vs
奥尼兰姆制药（ALNY）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是Rollins, Inc.的1.2倍（$1.1B vs $906.4M），奥尼兰姆制药净利率更高（17.0% vs 11.9%，领先5.1%），奥尼兰姆制药同比增速更快（84.9% vs 10.2%），奥尼兰姆制药自由现金流更多（$140.3M vs $111.2M），过去两年奥尼兰姆制药的营收复合增速更高（49.0% vs 0.8%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
ALNY vs ROL — 直观对比
营收规模更大
ALNY
是对方的1.2倍
$906.4M
营收增速更快
ALNY
高出74.7%
10.2%
净利率更高
ALNY
高出5.1%
11.9%
自由现金流更多
ALNY
多$29.0M
$111.2M
两年增速更快
ALNY
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $906.4M |
| 净利润 | $186.4M | $107.8M |
| 毛利率 | 75.6% | — |
| 营业利润率 | 12.0% | 16.1% |
| 净利率 | 17.0% | 11.9% |
| 营收同比 | 84.9% | 10.2% |
| 净利润同比 | 322.6% | 2.5% |
| 每股收益（稀释后） | $1.44 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.1B | $912.9M | ||
| Q3 25 | $1.2B | $1.0B | ||
| Q2 25 | $773.7M | $999.5M | ||
| Q1 25 | $594.2M | $822.5M | ||
| Q4 24 | $593.2M | $832.2M | ||
| Q3 24 | $500.9M | $916.3M | ||
| Q2 24 | $659.8M | $891.9M |
净利润ALNYROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $186.4M | $116.4M | ||
| Q3 25 | $251.1M | $163.5M | ||
| Q2 25 | $-66.3M | $141.5M | ||
| Q1 25 | $-57.5M | $105.2M | ||
| Q4 24 | $-83.8M | $105.7M | ||
| Q3 24 | $-111.6M | $136.9M | ||
| Q2 24 | $-16.9M | $129.4M |
毛利率ALNYROL
| Q1 26 | — | — | ||
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — |
营业利润率ALNYROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 12.0% | 17.5% | ||
| Q3 25 | 29.5% | 21.9% | ||
| Q2 25 | -2.1% | 19.8% | ||
| Q1 25 | 3.0% | 17.3% | ||
| Q4 24 | -17.7% | 18.1% | ||
| Q3 24 | -15.4% | 20.9% | ||
| Q2 24 | 7.4% | 20.4% |
净利率ALNYROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | 17.0% | 12.8% | ||
| Q3 25 | 20.1% | 15.9% | ||
| Q2 25 | -8.6% | 14.2% | ||
| Q1 25 | -9.7% | 12.8% | ||
| Q4 24 | -14.1% | 12.7% | ||
| Q3 24 | -22.3% | 14.9% | ||
| Q2 24 | -2.6% | 14.5% |
每股收益（稀释后）ALNYROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $1.44 | $0.24 | ||
| Q3 25 | $1.84 | $0.34 | ||
| Q2 25 | $-0.51 | $0.29 | ||
| Q1 25 | $-0.44 | $0.22 | ||
| Q4 24 | $-0.66 | $0.22 | ||
| Q3 24 | $-0.87 | $0.28 | ||
| Q2 24 | $-0.13 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $789.2M | $1.4B |
| 总资产 | $5.0B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资ALNYROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $1.7B | $100.0M | ||
| Q3 25 | $1.5B | $127.4M | ||
| Q2 25 | $1.1B | $123.0M | ||
| Q1 25 | $1.0B | $201.2M | ||
| Q4 24 | $966.4M | $89.6M | ||
| Q3 24 | $1.1B | $95.3M | ||
| Q2 24 | $968.5M | $106.7M |
总债务ALNYROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ALNYROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $789.2M | $1.4B | ||
| Q3 25 | $233.9M | $1.5B | ||
| Q2 25 | $250.6M | $1.4B | ||
| Q1 25 | $115.4M | $1.4B | ||
| Q4 24 | $67.1M | $1.3B | ||
| Q3 24 | $32.4M | $1.3B | ||
| Q2 24 | $-3.1M | $1.2B |
总资产ALNYROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $5.0B | $3.1B | ||
| Q3 25 | $4.9B | $3.2B | ||
| Q2 25 | $4.6B | $3.2B | ||
| Q1 25 | $4.2B | $2.9B | ||
| Q4 24 | $4.2B | $2.8B | ||
| Q3 24 | $4.2B | $2.8B | ||
| Q2 24 | $4.0B | $2.8B |
负债/权益比ALNYROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $163.6M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $140.3M | $111.2M |
| 自由现金流率自由现金流/营收 | 12.8% | 12.3% |
| 资本支出强度资本支出/营收 | 2.1% | 0.8% |
| 现金转化率经营现金流/净利润 | 0.88× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $465.4M | $621.1M |
8季度趋势，按日历期对齐
经营现金流ALNYROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $163.6M | $164.7M | ||
| Q3 25 | $325.1M | $191.3M | ||
| Q2 25 | $153.7M | $175.1M | ||
| Q1 25 | $-118.3M | $146.9M | ||
| Q4 24 | $-94.7M | $188.2M | ||
| Q3 24 | $43.7M | $146.9M | ||
| Q2 24 | $124.2M | $145.1M |
自由现金流ALNYROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $140.3M | $159.0M | ||
| Q3 25 | $313.0M | $182.8M | ||
| Q2 25 | $139.4M | $168.0M | ||
| Q1 25 | $-127.3M | $140.1M | ||
| Q4 24 | $-103.8M | $184.0M | ||
| Q3 24 | $39.5M | $139.4M | ||
| Q2 24 | $116.1M | $136.4M |
自由现金流率ALNYROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 12.8% | 17.4% | ||
| Q3 25 | 25.1% | 17.8% | ||
| Q2 25 | 18.0% | 16.8% | ||
| Q1 25 | -21.4% | 17.0% | ||
| Q4 24 | -17.5% | 22.1% | ||
| Q3 24 | 7.9% | 15.2% | ||
| Q2 24 | 17.6% | 15.3% |
资本支出强度ALNYROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.1% | 0.6% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 1.8% | 0.7% | ||
| Q1 25 | 1.5% | 0.8% | ||
| Q4 24 | 1.5% | 0.5% | ||
| Q3 24 | 0.8% | 0.8% | ||
| Q2 24 | 1.2% | 1.0% |
现金转化率ALNYROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 0.88× | 1.41× | ||
| Q3 25 | 1.29× | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| TTR | $858.3M | 78% |
| Rare | $136.4M | 12% |
| GIVLAARI | $56.3M | 5% |
| Collaborative Arrangement | $40.9M | 4% |
| ONPATTRO | $12.0M | 1% |
ROL
暂无分部数据
